New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis

Core Insights - The Quest AD-Detect® blood tests demonstrate high accuracy in identifying Alzheimer's disease pathology, potentially reducing the need for PET imaging confirmation [1][2][3] Test Performance - The study evaluated two blood tests with 91% sensitivity and 91% specificity in a population of 215 patients with mild cognitive impairment or Alzheimer's disease, where 46% were amyloid PET-positive [4][5] - The test combining AB 42/40, p-tau217, and ApoE4 had a positive predictive value (PPV) of 88% and a negative predictive value (NPV) of 91%, while the test without ApoE4 had a PPV of 87% and the same NPV [4] Indeterminate Results - The indeterminate rate was found to be 10% for the test with all three biomarkers and 15% for the test without ApoE4, aligning with recommendations that no more than 15%-20% of individuals should have indeterminate results [5] Market Context - Nearly 7 million Americans are diagnosed with Alzheimer's disease, projected to reach 14 million by 2060, highlighting the growing need for effective diagnostic tools [7] - Blood tests are considered more cost-effective compared to invasive methods like CSF lumbar puncture and PET imaging, which could benefit the healthcare system [8] Company Commitment - Quest Diagnostics is focused on developing innovative diagnostics for Alzheimer's disease and other brain diseases, aiming to improve patient care and health outcomes [8][9]